Red Light Holland Announces Corporate Rebrand to Rhelion Life Sciences Corp

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) is pleased to announce that it will be changing its corporate name to Rhelion Life Sciences Corp ( "Rhelion" ), marking the beginning of an exciting new chapter for the Company as it steps into its identity as a more focused science and research driven natural psychedelic drug discovery and development organization. The rebrand, pending the Canadian Securities Exchange ( "CSE") approval, follows the Company's completed acquisition of Filament Health Corp. and reflects a strategic evolution from the Company's origins into a focused clinical and research-led enterprise. Under the Rhelion name, the Company intends to build on the foundation of Filament's patented, naturally derived psilocybin drug candidate, PEX010, and its growing global network of clinical and compassionate use partners, while advancing an ambitious new research and development program. The rebrand ( www.Rhelion.com ) also comes at a time of accelerating momentum and growing investor enthusiasm across the psychedelic sector. That momentum was underscored on July 16, 2026, when Eli Lilly and Company announced an agreement to acquire AtaiBeckley for up to US$3.8 billion, one of the largest transactions to date in the sector and a clear signal of rising interest from major pharmaceutical companies in clinically de-risked psychedelic assets. "This name change represents so much more than a new name. It represents everything we have been building toward when it comes to increasing responsible and standardized psychedelic access - from underground to mainstream," said Todd Shapiro, Chief Executive Officer and Director of the Company. "Rhelion reflects the company we have become: a science first, research driven organization with a world class drug development platform, a growing program, and a bold vision for the future of natural psychedelic medicine. The timing is perfect. The sector is gaining real momentum, major pharmaceutical companies are moving decisively into psychedelics, and we intend to build genuine, de-risked value for our shareholders. Rhelion Life Sciences: Rediscover Health represents the next evolution of science-backed innovation focused on long-term mental wellness and conscious human advancement." The company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. The company recently announced that Filament Health is introducing a new 0.5 mg dose alongside its existing 1, 5 and 25 mg strengths of PEX010, giving researchers a standardized range of 0.5, 1, 5 and 25 mg from a single drug candidate, from sub-hallucinogenic microdosing through to full therapeutic doses. PEX010 is produced using Filament's proprietary extraction, purification, and stabilization methods, which deliver a potent yet standardized and patented botanical drug product with consistent composition across every dose, every study, and every research site. That consistency is protected by a broad international patent portfolio and backed by a demonstrated 36-month shelf life. PEX010 offers reproducibility at scale, a composition that does not drift from one production run to the next, allowing investigators to attribute their findings to the compound itself rather than to batch-to-batch variation. This development, plus the future focused direction of the company reflects continued demand for pharmaceutical-grade, naturally d...